<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2767546</article-id><article-id pub-id-type="publisher-id">1742-4690-6-S3-O25</article-id><article-id pub-id-type="doi">10.1186/1742-4690-6-S3-O25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Salmon-C&#x000e9;ron</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A2" contrib-type="author"><name><surname>Durier</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Desaint</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Cuzin</surname></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Surenaud</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A6" contrib-type="author"><name><surname>H&#x000e9;nin</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib id="A7" contrib-type="author"><name><surname>Leli&#x000e8;vre</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib id="A8" contrib-type="author"><name><surname>Bonnet</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib id="A9" contrib-type="author"><name><surname>Pialoux</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib id="A10" contrib-type="author"><name><surname>Poizot-Martin</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib id="A11" contrib-type="author"><name><surname>Ben Hamouda</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A12" contrib-type="author"><name><surname>Jackson</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A13" contrib-type="author"><name><surname>Flys</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A14" contrib-type="author"><name><surname>Gu&#x000e9;rin</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib id="A15" contrib-type="author"><name><surname>Aboulker</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A16" contrib-type="author"><name><surname>Choppin</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A17" contrib-type="author"><name><surname>Launay</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib></contrib-group><aff id="I1"><label>1</label>H&#x000f4;pital Cochin, Universit&#x000e9; Paris Descartes, Paris, France</aff><aff id="I2"><label>2</label>Inserm, SC10, Villejuif, France</aff><aff id="I3"><label>3</label>CIC de Vaccinologie Cochin-Pasteur, Paris, France</aff><aff id="I4"><label>4</label>H&#x000f4;pital Purpan, Toulouse, France</aff><aff id="I5"><label>5</label>Institut Cochin, Universit&#x000e9; Paris Descartes, CNRS (UMR 8104), Inserm U567, Paris, France</aff><aff id="I6"><label>6</label>H&#x000f4;pital Henri Mondor, Universit&#x000e9; Paris 12, Cr&#x000e9;teil, France</aff><aff id="I7"><label>7</label>H&#x000f4;pital H&#x000f4;tel-Dieu, Nantes, France</aff><aff id="I8"><label>8</label>H&#x000f4;pital Tenon, Paris, France</aff><aff id="I9"><label>9</label>H&#x000f4;pital Sainte Marguerite, Marseille, France</aff><aff id="I10"><label>10</label>CIC de Vaccinologie Cochin-Pasteur, H&#x000f4;pital Cochin, Universit&#x000e9; Paris Descartes, Paris, France</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2009</year></pub-date><volume>6</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">AIDS Vaccine 2009</named-content><named-content content-type="supplement-editor">Anna Laura Ross</named-content></supplement><fpage>O25</fpage><lpage>O25</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/6/S3/O25"/><permissions><copyright-statement>Copyright &#x000a9; 2009 Salmon-C&#x000e9;ron et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Salmon-C&#x000e9;ron et al; licensee BioMed Central Ltd.</copyright-holder></permissions><conference><conf-date>19&#x02013;22 October 2009</conf-date><conf-name>AIDS Vaccine 2009</conf-name><conf-loc>Paris, France</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>ANRS HIV-LIPO-5 vaccine includes 5 long peptides, Gag17&#x02013;35, 253&#x02013;284, Pol325&#x02013;355, Nef66&#x02013;97 and 116&#x02013;145, containing multiple CD8+ and CD4+ T-cell epitopes, coupled to a palmytoil tail. Phase 1 studies have shown that vaccine dosage at 500 &#x003bc;g/lipopeptide elicits cellular immune responses. Whether HIV-LIPO5 immunogenicity varies with the dosage is unknown.</p></sec><sec sec-type="methods"><title>Methods</title><p>One hundred and thirty two 21- to 55-year-old HIV negative volunteers, enrolled in 6 HIV-vaccine clinical sites, were randomized to receive either the HIV-LIPO-5 vaccine at 50 &#x003bc;g/lipopeptide (N = 32; LIPO-5 50), 150 &#x003bc;g (N = 32; LIPO-5 150), 500 &#x003bc;g (N = 33; LIPO-5 500) or placebo (N = 34). Vaccinations were given IM at weeks 0, 4, 12 and 24. HIV-1 specific CD8+ (IFN-gamma ELISpot on PBMC cultured 12-days) and CD4+ responses (PBMC lymphoproliferation) were assessed at baseline, two weeks after each injection, and at week 48.</p></sec><sec><title>Results</title><p>No adverse events attributable to vaccine were noted throughout the study. Local reactions appeared dose-dependent; no differences in systemic reactions were observed between groups. Sustained (at least on 2 separate occasions) CD8+ response rates to at least one HIV-1 pool were: 5/32 (16%) for placebo, 22/32 (69%) for LIPO-5 50, 21/33 (64%) for LIPO-5 150 and 21/34 (62%) for LIPO-5 500 groups (P &#x02264; .0001 for all comparisons to placebo). Cumulative CD4+ response rates were: placebo: 2/32 (6%), LIPO-5 50: 15/32 (47%), LIPO-5 150: 18/33 (55%) and LIPO-5 500: 15/34 (44%) (P &#x0003c; .0001 for all comparisons to placebo). The majority of CD4+ (75%) and CD8+ (60%) responses were directed towards Gag253&#x02013;284. CD8+ responses against Nef, Pol were noted in 36% and 33% of vaccinees, respectively. At week 48, CD8+ responses persisted in 47/91 (52%) HIV-LIPO-5 recipients.</p></sec><sec><title>Conclusion</title><p>ANRS VAC18 shows that low and high doses of HIV-LIPO-5 vaccine elicit sustained CD8+ and CD4+ T-cell responses. According to the good tolerance of the vaccine, the lowest dose of 50 &#x003bc;g appears as the most appropriate to be used in further trials.</p></sec></body></article>


